scholarly journals Prognostic significance of the systemic immune-inflammation index in pancreatic carcinoma patients: A meta-analysis

2021 ◽  
Author(s):  
Xiaocheng Li ◽  
Huapeng Lin ◽  
Renbin Ouyang ◽  
Yaowei Yang ◽  
Jing Peng
Keyword(s):  
Pancreatic Carcinoma ◽  
Fixed Effects ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Prognostic Indicator ◽  
Cochrane Library ◽  
Cancer Specific Survival ◽  
Non Invasive ◽  
Promising Tool ◽  
Immune Inflammation

Background: Systemic immune-inflammation index (SII) is a prognostic indicator for several malignancies, including pancreatic carcinoma, however, there is no consensus on its significance. In the current study, a systematic meta-analysis was used to explore the correlation between SII and prognosis in pancreatic carcinoma patients. Methods: PubMed, Embase and Cochrane Library databases were screened from inception to May 2020. Studies describing the prognostic role of SII in pancreatic carcinoma were then retrieved. The pooled hazard ratio (HR) and 95% confidence interval (CI) was calculated using random or fixed effects models to determine the correlation between SII and prognosis. Results: A total of 4 studies, comprising 1,749 patients, met the inclusion criteria of the study and were therefore included in this meta-analysis. The meta-analysis showed that high SII indicated was correlated with worse overall survival in patients with pancreatic carcinoma (HR: 1.43, 95% CI: 1.24-1.65, P < 0.001). These findings were validated through subgroup analyses, stratified by the AJCC stage. In addition, patients with high SII showed poorer cancer-specific survival (HR: 2.32, 95% CI: 1.55-3.48, P < 0.001). However, analysis showed no significant correlations between SII and disease-free and relapse-free survival. Conclusion: These findings indicate that SII is a potential non-invasive and a promising tool for predicting clinical outcomes of pancreatic carcinoma patients. However, the current research did not explore whether neoadjuvant therapy has an effect on the prognostic value of SII. Further studies using adequate designs and larger sample sizes are required to validate these findings.

scholarly journals Systemic immune‐inflammation index has prognostic significance in pancreatic carcinoma patients: a meta-analysis

2021 ◽  
Author(s):  
Xiaocheng Li ◽  
Huapeng Lin ◽  
Renbin Ouyang ◽  
Yaowei Yang ◽  
Jing Peng
Keyword(s):  
Pancreatic Carcinoma ◽  
Fixed Effects ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Prognostic Indicator ◽  
Cochrane Library ◽  
Cancer Specific Survival ◽  
Non Invasive ◽  
Promising Tool ◽  
Immune Inflammation

Abstract Background Systemic immune-inflammation index (SII) is reportedly a prognostic indicator for several malignancies, including pancreatic carcinoma, although there exists no consensus regarding its significance. In the current study, we used a systematically meta-analysis to evaluate the association between SII and prognosis in pancreatic carcinoma patients. Methods We screened PubMed, Embase and Cochrane Library databases, through May 2020, and retrieved studies describing the prognostic role of SII in pancreatic carcinoma. We calculated pooled hazard ratio (HR) and 95% confidence interval (CI) using a random or fixed effects models to reveal the correlation between SII and prognosis. Results A total of 4 studies, comprising 1,749 patients, met our inclusion criteria and were therefore eligible for inclusion. Our meta-analysis showed that elevated SII indicated significantly worse overall survival in patients with pancreatic carcinoma (HR: 1.43, 95% CI: 1.24–1.65, P < 0.001), with subgroup analyses, stratified by the TNM stage and treatment, further validating these results. In addition, patients with high SII had poorer cancer-specific survival (HR: 2.32, 95% CI: 1.55–3.48, P < 0.001). However, we found no significant associations between SII with disease-free and relapse-free survival. Conclusions These findings indicate that SII is a potential non-invasive and promising tool for predicting clinical outcomes of pancreatic carcinoma patients. However, further studies using adequate designs and larger sample sizes are required to validate our findings.

scholarly journals Systemic Immune‐Inflammation Index Has Prognostic Significance In Pancreatic Carcinoma Patients: A Meta-Analysis

2020 ◽  
Author(s):  
Xiaocheng Li ◽  
Huapeng Lin ◽  
Renbin Ouyang ◽  
Yaowei Yang ◽  
Jing Peng
Keyword(s):  
Pancreatic Carcinoma ◽  
Fixed Effects ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Prognostic Indicator ◽  
Cochrane Library ◽  
Cancer Specific Survival ◽  
Non Invasive ◽  
Promising Tool ◽  
Immune Inflammation

Abstract Background: Systemic immune-inflammation index (SII) is reportedly a prognostic indicator for several malignancies, including pancreatic carcinoma, although there exists no consensus regarding its significance. In the current study, we used a systematically meta-analysis to evaluate the association between SII and prognosis in pancreatic carcinoma patients.Methods: We screened PubMed, Embase and Cochrane Library databases, through May 2020, and retrieved studies describing the prognostic role of SII in pancreatic carcinoma. We calculated pooled hazard ratio (HR) and 95% confidence interval (CI) using a random or fixed effects models to reveal the correlation between SII and prognosis.Results: A total of 4 studies, comprising 1,749 patients, met our inclusion criteria and were therefore eligible for inclusion. Our meta-analysis showed that elevated SII indicated significantly worse overall survival in patients with pancreatic carcinoma (HR: 1.43, 95% CI: 1.24-1.65, P < 0.001), with subgroup analyses, stratified by the TNM stage and treatment, further validating these results. In addition, patients with high SII had poorer cancer-specific survival (HR: 2.32, 95% CI: 1.55-3.48, P < 0.001). However, we found no significant associations between SII with disease-free and relapse-free survival.Conclusions: These findings indicate that SII is a potential non-invasive and promising tool for predicting clinical outcomes of pancreatic carcinoma patients. However, further studies using adequate designs and larger sample sizes are required to validate our findings.

scholarly journals Systemic Immune-Inflammation Index is a Promising Noninvasive Biomarker for Predicting the Survival of Urinary System Cancers: A Systematic Review and Meta-Analysis

2021 ◽  
Author(s):  
Xing Li ◽  
Lijiang Gu ◽  
Yuhang Chen ◽  
Yue Chong ◽  
Xinyang Wang ◽  
...  
Keyword(s):  
Meta Analysis ◽  
Tumour Size ◽  
Prognostic Significance ◽  
Progression Free Survival ◽  
Cochrane Library ◽  
Clinicopathological Parameters ◽  
Urinary System ◽  
Cancer Specific Survival ◽  
Immune Inflammation ◽  
Mean Differences

Abstract Purpose: Systemic immune-inflammation index (SII) has been reported in numerous studies to effectively predict the pathological features and survival outcomes of urinary system cancers, but no agreement has been reached. The aim of this meta-analysis is to explore the prognostic significance of pretreatment SII in tumours of the urinary system.Methods: Relevant published articles were selected from Web of Science, PubMed, Embase, and the Cochrane Library up to August 30, 2020. The pooled hazard ratios (HRs), odds ratios (ORs), and standard mean differences (SMDs) with 95% confidence intervals (CIs) were computed to estimate the associations of pretreatment SII with overall survival (OS), progression-free survival (PFS), cancer-specific survival (CSS), and clinicopathological parameters in urinary system cancers.Results: Overall, a total of 13 papers published from 2016 to 2020 involving 15 datasets comprising 3974 patients were finally included in our meta-analysis. From the combined data, we found that high SII prior to treatment indicated markedly worse OS (HR =1.98, 95% CI: 1.75–2.23; p < 0.001), PFS (HR: 2.08, 95% CI: 1.32–3.26, p = 0.002) with high heterogeneity (I2 = 80.8%, p < 0.001), and CSS (HR: 2.41, 95% CI: 1.73–3.35, p < 0.001). In addition, patients who have an elevated SII value before receiving treatment might have undesirable pathological characteristics, including large tumour size, poor differentiation grade, and advanced tumour stage (all p < 0.001).Conclusion: Pretreatment SII could be used as a noninvasive and promising biomarker for indicating the prognosis of patients with urinary system cancers.

scholarly journals Prognostic significance of pretreatment controlling nutritional status score in urological cancers: a systematic review and meta‐analysis

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Xinhao Niu ◽  
Zhe Zhu ◽  
Juan Bao
Keyword(s):  
Nutritional Status ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Prognostic Indicator ◽  
Cochrane Library ◽  
Cancer Type ◽  
Cancer Specific Survival ◽  
Urological Cancers ◽  
The Cochrane Library ◽  
Conut Score

Abstract Background Controlling Nutritional Status (CONUT) score is a novel nutrition-based biomarker that has been reported for predicting survival in various cancers. However, the relationship between CONUT score and prognosis of urological cancers remains unclear. Hence, we performed this meta-analysis to evaluate the prognostic significance of CONUT score for patients with urological cancers. Methods PubMed, Embase, the Cochrane Library and National Knowledge Infrastructure (CNKI) were systematically searched up to October 2020. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to evaluate the association of CONUT score with overall survival (OS), cancer-specific survival (CSS) and recurrence/disease/progress-free survival (RFS/DFS/PFS) in urological cancers. Results A total of 12 articles with 13 studies were included in the analysis. Pooled results indicated that increased CONUT score predicted poor OS (HR: 1.78, 95% CI 1.51–2.09, p < 0.001), CSS (HR: 2.14, 95% CI 1.55–2.97, p < 0.001) and RFS/DFS/PFS (HR: 1.57, 95% CI 1.35–1.84, p < 0.001). Subgroup analysis by cancer type revealed that high CONUT score associated with worse OS in renal cell carcinoma (RCC) and urothelial cancer (UC) (HR: 3.05, 95% CI 2.07–4.50, p < 0.001; HR: 1.58, 95% CI 1.32–1.89, p < 0.001). Similar results could be found in CSS (RCC HR: 2.67, 95% CI 1.87–3.81, p < 0.011; UC HR: 1.68, 95% CI 1.09–2.59, p = 0.011) and in RFS/DFS/PFS (RCC HR: 1.96, 95% CI 1.44–2.66, p < 0.001; UC HR: 1.42, 95% CI 1.18–1.71, p < 0.001). Conclusions These results illustrated that the high CONUT score may predict worse survival for patients suffering from urological cancers. Therefore, the CONUT score may represent an effective prognostic indicator in urological cancers.

scholarly journals The Prognostic Roles and Clinical Features of CD44v9 in Human Solid Cancers—A Meta-Analysis

2020 ◽  
Author(s):  
Yuanxiu Deng ◽  
Jie Wang ◽  
Shenhui Ji ◽  
Lu Huang ◽  
Meijiang Feng
Keyword(s):  
Clinical Features ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Disease Free Survival ◽  
Progression Free Survival ◽  
High Expression ◽  
Cochrane Library ◽  
Cancer Specific Survival ◽  
Free Survival ◽  
Diagnosis And Prognosis

Abstract Background: CD44 is the primary receptor for hyaluronic acid and serves as a marker for cancer stem cells. CD44v9 is one of CD44’s variants and takes part in cancer’s growth and metastasis. However, the prognostic roles and clinical features of CD44v9 in cancers remain unclear. Therefore, we conducted this meta-analysis to summarize the prognostic significance and clinical features of CD44v9 in human solid cancers.Methods: we systematically searched all of related studies in PubMed, the Web of Science, Embase and Cochrane library up to June 2020. We analyzed the pooled hazard ratios (HRs) and odds ratios (ORs) with corresponding 95% confidence intervals (CIs) to assess the prognostic functions and clinical features of CD44v9 in various human solid cancers.Results: In this meta-analysis, we included 1705 cancer patients among 12 studies. Results indicated that high expression of CD44v9 was significantly related to poorer overall survival (OS) (HR=1.60, 95%CI 1.28-1.99, P<0.0001), recurrence-free survival/progression-free survival/disease-free survival (RFS/PFS/DFS).( HR=1.81, 95%CI 1.16-2.84, P=0.009) and disease-specific survival/cancer-specific survival (DSS/CSS) (HR=2.93, 95%CI 1.69-5.10, P<0.001). At the same time, we also found that high expression of CD44v9 increased the possibility of lymphoid infiltrates (OR=1.59, 95%CI 1.16-2.20, P=0.005), vascular invasion (OR=1.57, 95%CI 1.11-2.22, P=0.010) and higher TNM stage (OR=1.63, 95%CI 1.19-2.23, P=0.002).Conclusion: Our results demonstrate that CD44v9 overexpression is associated with worse OS, RFS/PFS/CFS and DSS/CSS in patients with solid cancers, which might be a biomarker in the diagnosis and prognosis of cancers in the future.

scholarly journals Prognostic significance of platelet-to-lymphocyte ratio in urothelial carcinoma patients: a meta-analysis

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Yuhai Bao ◽  
Yin Wang ◽  
Xiaodong Li ◽  
Mingjun Pan ◽  
Hongze Zhang ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Disease Free Survival ◽  
Cochrane Library ◽  
Prognostic Impact ◽  
Platelet To Lymphocyte Ratio ◽  
Cancer Specific Survival ◽  
Free Survival ◽  
Lymphocyte Ratio

Abstract Background The prognostic value of pre-treatment platelet-to-lymphocyte ratio (PLR) in patients with urothelial carcinoma (UC) remains controversial. Therefore, this meta-analysis aimed to identify the prognostic impact of PLR on UC. Methods The PubMed, Embase, Web of Science, and Cochrane Library databases were systematically searched. Hazard ratios (HRs) with 95% confidence intervals (CIs) were used to summarize the correlations between PLR and overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), and cancer-specific survival (CSS). Odds ratios (ORs) with 95% CIs were used to measure the association between PLR and tumor clinicopathological factors. Results The meta-analysis included 15 studies published from 2015 to 2019 with a total of 5354 patients. Overall, a high PLR was correlated to poorer PFS (HR = 1.81, 95% CI 1.28–2.56, p = 0.001) and DFS (HR = 1.09, 95% CI 1.31–2.16, p < 0.001) but not poor OS (HR = 1.23, 95% CI 0.95–1.59, p = 0.124) or CSS (HR = 1.000, 95% CI 0.998–1.002, p = 0.919) in UC. In addition, an elevated PLR was correlated with patient age > 65 years (OR = 1.72, 95% CI 1.25–2.38, p = 0.001) and hypertension (OR = 1.48, 95% CI 1.01–2.18, p = 0.046). However, no significant association was observed between PLR and sex (OR = 0.79, 95% CI 0.56–1.14, p = 0.206) or diabetes (OR = 1.29, 95% CI 0.77–2.15, p = 0.333). Conclusions Our results demonstrated a significant correlation between elevated PLR and poor prognosis in UC. The prognostic role of PLR may help guide the management and prognostication of UC patients.

scholarly journals Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis

2020 ◽  
Author(s):  
Juli Lin ◽  
Jian-xian Lin ◽  
Chao-hui Zheng ◽  
Ping Li ◽  
Jian-wei Xie ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Overall Survival ◽  
Survival Benefit ◽  
Fixed Effects ◽  
Meta Analysis ◽  
Colorectal Cancer Patient ◽  
Cochrane Library ◽  
Cancer Specific Survival ◽  
Gastric Cancers ◽  
Cox 2

Abstract Background: Many studies have found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer. Methods: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted,, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users. Data extraction and quality evaluation were independently conducted by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer-specific survival by using either a fixed-effects model or a random-effects model. Results: A total of 18 studies were included in this meta-analysis, with more than 74,936 patients. There were no significant differences between postdiagnosis aspirin use and overall survival for esophageal and gastric cancers. For colorectal cancer, a benefit that was associated with postdiagnosis aspirin use was observed for overall survival and cancer-specific survival [HR= 0.83, 95%CI(0.75, 0.9.);HR= 0.78, 95%CI(0.66, 0.92), respectively. However, a prediagnosis of aspirin use did not provide a benefit for overall or cancer-specific survival in colorectal cancer. HR values for overall and cancer-specific survival benefits for colorectal cancer associated with both prediagnosis and postdiagnosis aspirin were as follows: HR=0.75，95%CI(0.61, 0.92) and HR=0.78, 95%CI(0.73, 0.85), respectively. In addition, the survival benefit of postdiagnosis aspirin use appeared to be confined to patients with mutated PIK3CA tumors [HR= 0.78, 95%CI(0.50, 0.99)] and was positive for PTGS2 (COX-2) expression [HR= 0.75, 95%CI(0.43, 1.30)]. Conclusions: These findings provide further indications that postdiagnosis aspirin use improves overall survival and cancer-specific survival in colorectal cancer, especially for patients who are positive for PTGS2 (COX-2) expression and PIK3CA-mutated tumors. However, aspirin therapy does not improve overall survival in esophageal and gastric cancers, although the meta-analysis was mainly limited to retrospective studies.

scholarly journals Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis

2019 ◽  
Author(s):  
Juli Lin ◽  
Jian-xian Lin ◽  
Chao-hui Zheng ◽  
Ping Li ◽  
Jian-wei Xie ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Gastric Cancer ◽  
Overall Survival ◽  
Survival Benefit ◽  
Fixed Effects ◽  
Meta Analysis ◽  
Colorectal Cancer Patient ◽  
Cochrane Library ◽  
Cancer Specific Survival ◽  
Cox 2

Abstract Background: Many studies have found that use of aspirin can lengthen survival of gastrointestinal cancer. The aim of this study is to assess the survival benefit of aspirin use compared with non- aspirin use for patients with esophageal, gastric or colorectal cancer. Methods: We search online databases, including PubMed、Cochrane Library、Embase and www.clinicaltrials.gov before Feb 1th, 2019 to identify all relevant studies. The overall survival and cancer specific survival of esophageal, gastric and colorectal cancer in aspirin users compared with non-aspirin users. Data extraction and evaluation of studies’ quality were conducted independently by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer specific survival using either a fixed-effects or a random-effects model. Results: 17 studies were finally included in this meta-analysis, comprising more than 71,534 patients. There is no significant differences between post-diagnosis aspirin use and overall survival for esophageal and gastric cancer. The overall survival and cancer specific survival for colorectal cancer benefit associated with post-diagnosis aspirin use represented ［HR= 0.82, 95%CI(0.72, 0.94)］ and［HR= 0.70, 95%CI(0.57, 0.86)］. Overall survival and cancer specific survival for colorectal cancer did not benefit associated with aspirin use pre-diagnosis. The overall survival and cancer specific survival for colorectal cancer benefit associated with both pre and post-diagnosis aspirin use represented［HR=0.75，95%CI(0.61, 0.92)］and［HR=0.78, 95%CI(0.73, 0.85)］. Besides, the survival benefit of post-diagnosis aspirin use appeared to be confined to those patients with mutated PIK3CA tumors［HR= 0.78, 95%CI(0.50, 0.99)］and with positive PTGS2 (COX-2) expression［HR= 0.75, 95%CI(0.43, 1.30)］. Conclusions: These findings provide further indication that post-diagnosis aspirin therapy improved overall survival and cancer specific survival of colorectal cancer, especially for patients with positive PTGS2 (COX-2) expression and mutated PIK3CA tumors. However, it don’t improve overall survival of esophageal and gastric cancer and the meta-analysis is limited mainly to retrospective studies.

scholarly journals Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis

2020 ◽  
Author(s):  
Juli Lin ◽  
Jian-xian Lin ◽  
Chao-hui Zheng ◽  
Ping Li ◽  
Jian-wei Xie ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Overall Survival ◽  
Survival Benefit ◽  
Fixed Effects ◽  
Meta Analysis ◽  
Colorectal Cancer Patient ◽  
Cochrane Library ◽  
Cancer Specific Survival ◽  
Gastric Cancers ◽  
Cox 2

Abstract Background: Many studies have found that use of aspirin can lengthen survival in patients with gastrointestinal cancer. The aim of this study was to assess the survival benefit of aspirin use compared with non-aspirin use for patients with esophageal, gastric or colorectal cancer.Methods: We searched online databases, including PubMed, the Cochrane Library, Embase and www.clinicaltrials.gov for studies that were conducted, before April 30th, 2020, to identify relevant studies. Overall survival and cancer-specific survival of esophageal, gastric and colorectal cancers among aspirin users were compared with those among non-aspirin users. Data extraction and quality evaluation were independently conducted by 2 investigators. A meta-analysis was performed to calculate the pooled risk ratios (RRs) for overall survival and cancer-specific survival by using either a fixed-effects model or a random-effects model.Results: A total of 18 studies were included in this meta-analysis, with more than 74,936 patients. There were no significant differences between postdiagnosis aspirin use and overall survival for esophageal and gastric cancers. For colorectal cancer, a benefit that was associated with postdiagnosis aspirin use was observed for overall survival and cancer-specific survival [HR= 0.83, 95%CI(0.75, 0.9.);HR= 0.78, 95%CI(0.66, 0.92), respectively. However, a prediagnosis of aspirin use did not provide a benefit for overall or cancer-specific survival in colorectal cancer. HR values for overall and cancer-specific survival benefits for colorectal cancer associated with both prediagnosis and postdiagnosis aspirin were as follows: HR=0.75，95%CI(0.61, 0.92) and HR=0.78, 95%CI(0.73, 0.85), respectively. In addition, the survival benefit of postdiagnosis aspirin use appeared to be confined to patients with mutated PIK3CA tumors [HR= 0.78, 95%CI(0.50, 0.99)] and was positive for PTGS2 (COX-2) expression [HR= 0.75, 95%CI(0.43, 1.30)].Conclusions: These findings provide further indications that postdiagnosis aspirin use improves overall survival and cancer-specific survival in colorectal cancer, especially for patients who are positive for PTGS2 (COX-2) expression and PIK3CA-mutated tumors. However, aspirin therapy does not improve overall survival in esophageal and gastric cancers, although the meta-analysis was mainly limited to retrospective studies.

scholarly journals Prognostic Significance of Pretreatment Apolipoprotein A-I as a Noninvasive Biomarker in Cancer Survivors: A Meta-Analysis

2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Yi Zhang ◽  
Xianjin Yang
Keyword(s):  
Meta Analysis ◽  
Prognostic Significance ◽  
Disease Free Survival ◽  
Cancer Prognosis ◽  
Cochrane Library ◽  
China National Knowledge Infrastructure ◽  
Poor Overall Survival ◽  
Cancer Specific Survival ◽  
Free Survival ◽  
Apolipoprotein A

Background. Numerous studies have reported the prognostic significance of serum apolipoprotein A-I (ApoA-I) in various cancers, but the results have been inconsistent. The current meta-analysis was performed to investigate the association between ApoA-I level and prognosis in human malignancies. Methods. A literature search was performed using the electronic platforms of the PubMed, Cochrane Library, Web of Science, Embase, Wanfang, and China National Knowledge Infrastructure (CNKI) databases to obtain eligible articles published up to May 20, 2018. Pooled hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated to assess the prognostic values of the ApoA-I level in cancers using STATA 12.0 software. Results. A total of 14 studies involving 9295 patients were included. The results indicated that low ApoA-I level was significantly associated with poor overall survival (OS) (HR = 0.52, 95% CI: 0.44–0.61). Significant relationships between the ApoA-I level and OS were specifically detected in nasopharyngeal carcinoma (NPC, HR = 0.63, 95% CI: 0.54–0.73), colorectal cancer (CRC, HR = 0.48, 95% CI: 0.19–0.76), and hepatocellular carcinoma (HCC, HR = 0.46, 95% CI: 0.27–0.65). The subgroup analyses for OS also further confirmed the prognostic significance of the ApoA-I level in cancers. Moreover, lower Apo A-I was associated with unfavorable cancer-specific survival (CSS, HR: 0.47, 95% CI: 0.19–0.76) in cancers, and low ApoA-I level was clearly associated with inferior total time to recurrence (TTR, HR: 0.43, 95% CI: 0.29–0.58) in HCC, poorer locoregional recurrence-free survival (LRFS) and distant metastasis-free survival (DMFS) (HR: 0.58, 95% CI: 0.42–0.74 for LRFS; HR: 0.65, 95% CI: 0.41–0.89 for DMFS) in NPC, and shorter disease-free survival (DFS, HR: 0.64, 95% CI: 0.43–0.84) in cancers. Conclusions. Low ApoA-I level might be an unfavorable prognostic factor in multiple malignancies, and serum ApoA-I could serve as a noninvasive marker to predict cancer prognosis.

Sign in / Sign up

Export Citation Format

Share Document